Microneedle technologies have the potential for expanding the capabilities of wearable health monitoring from physiology to biochemistry.This paper presents the fabrication of silicon hollow microneedles by a deep-rea...Microneedle technologies have the potential for expanding the capabilities of wearable health monitoring from physiology to biochemistry.This paper presents the fabrication of silicon hollow microneedles by a deep-reactive ion etching(DRIE)process,with the aim of exploring the feasibility of microneedle-based in-vivo monitoring of biomarkers in skin fluid.Such devices shall have the ability to allow the sensing elements to be integrated either within the needle borehole or on the backside of the device,relying on capillary filling of the borehole with dermal interstitial fluid(ISF)for transporting clinically relevant biomarkers to the sensor sites.The modified DRIE process was utilized for the anisotropic etching of circular holes with diameters as small as 30μm to a depth of>300μm by enhancing ion bombardment to efficiently remove the fluorocarbon passivation polymer.Afterward,isotropic wet and/or dry etching was utilized to sharpen the needle due to faster etching at the pillar top,achieving tip radii as small as 5μm.Such sharp microneedles have been demonstrated to be sufficiently robust to penetrate porcine skin without needing any aids such as an impact-insertion applicator,with the needles remaining mechanically intact after repetitive penetrations.The capillary filling of DRIE-etched through-wafer holes with water has also been demonstrated,showing the feasibility of use to transport the analyte to the target sites.展开更多
Dear Editor,Diffuse large B-cell lymphoma(DLBCL)is the most common and aggressive subtype of non-Hodgkin lymphoma(NHL),accounting for about 40%of all NHL cases[1].Lacking symptoms at early time and efficient therapeut...Dear Editor,Diffuse large B-cell lymphoma(DLBCL)is the most common and aggressive subtype of non-Hodgkin lymphoma(NHL),accounting for about 40%of all NHL cases[1].Lacking symptoms at early time and efficient therapeutic methods made DLBCL one of the most life-threatening types of hematopoietic malignancy[2,3].Therefore,identifying novel therapeutic biomarker for early detection and prognosis prediction is urgently needed.展开更多
基金The work was funded by ExVivo Labs Inc.,OCE and NSERC.
文摘Microneedle technologies have the potential for expanding the capabilities of wearable health monitoring from physiology to biochemistry.This paper presents the fabrication of silicon hollow microneedles by a deep-reactive ion etching(DRIE)process,with the aim of exploring the feasibility of microneedle-based in-vivo monitoring of biomarkers in skin fluid.Such devices shall have the ability to allow the sensing elements to be integrated either within the needle borehole or on the backside of the device,relying on capillary filling of the borehole with dermal interstitial fluid(ISF)for transporting clinically relevant biomarkers to the sensor sites.The modified DRIE process was utilized for the anisotropic etching of circular holes with diameters as small as 30μm to a depth of>300μm by enhancing ion bombardment to efficiently remove the fluorocarbon passivation polymer.Afterward,isotropic wet and/or dry etching was utilized to sharpen the needle due to faster etching at the pillar top,achieving tip radii as small as 5μm.Such sharp microneedles have been demonstrated to be sufficiently robust to penetrate porcine skin without needing any aids such as an impact-insertion applicator,with the needles remaining mechanically intact after repetitive penetrations.The capillary filling of DRIE-etched through-wafer holes with water has also been demonstrated,showing the feasibility of use to transport the analyte to the target sites.
基金This work was supported by the National Natural Science Foundation of China(81802424).
文摘Dear Editor,Diffuse large B-cell lymphoma(DLBCL)is the most common and aggressive subtype of non-Hodgkin lymphoma(NHL),accounting for about 40%of all NHL cases[1].Lacking symptoms at early time and efficient therapeutic methods made DLBCL one of the most life-threatening types of hematopoietic malignancy[2,3].Therefore,identifying novel therapeutic biomarker for early detection and prognosis prediction is urgently needed.
